Our results showed that the occurrence of MSI and LOH was highest in the Tp53-Alu microsatellite among the markers screened, and it was also found to correlate with low or deficient expression of the hMSH2 and P53 proteins in the de novo breast cancer patients after chemotherapy. Here, TP53 is linked to breast cancer.